EBR Systems Completes Retail Entitlement Offer Raising A$10.9 Million

Retail Entitlement Offer Completion

EBR Systems (ASX:EBR) has successfully closed the retail portion of its 1-for-2 pro-rata accelerated non-renounceable entitlement offer, securing around A$10.9 million. This retail round marks the final phase of the company’s capital raise, which totals approximately A$43.6 million at an issue price of A$0.38 per new CHESS Depositary Interest (CDI). The institutional leg of the entitlement offer concluded earlier in June.

The retail offer attracted valid applications for nearly 28.8 million new CDIs, including about 5.9 million under a top-up facility. Applications exceeding the 100% cap were scaled back slightly. Meanwhile, entitlements from ineligible retail securityholders and those not taken up amounting to roughly 85.9 million new CDIs will be placed by the joint lead managers (JLMs) Canaccord Genuity Australia, E&P Capital, and Morgans Corporate, who fully underwrote the retail offer.

Trading and Capital Structure Impact

The new CDIs are scheduled for issuance on 29 June 2026, with trading expected to commence on the ASX the following day. These securities will rank equally with existing CDIs from the date of issue, maintaining shareholder rights and entitlements.

While the announcement does not specify the precise use of the proceeds, the capital injection is expected to bolster EBR’s commercialisation efforts for its WiSE wireless cardiac pacing system. This technology aims to revolutionise heart failure treatment by eliminating the need for traditional pacing leads, a known source of complications in cardiac resynchronisation therapy.

EBR’s Wireless Cardiac Pacing Innovation

EBR’s WiSE technology remains the only wireless endocardial pacing system in clinical use for left ventricular stimulation. The implant, roughly the size of a grain of rice, offers a novel alternative to conventional leads placed on the heart’s surface, potentially improving patient outcomes. The company’s focus on this platform aligns with broader efforts to expand indications beyond heart failure, including bradycardia and other applications.

In recent months, EBR has been advancing its US commercial footprint through strategic hospital agreements and regulatory progress, including a Medicare review fast-tracked by the Centers for Medicare & Medicaid Services. These developments underscore the importance of the current capital raise in supporting ongoing growth initiatives.